Lantheus Posts $389.9M in Q3 Revenue, Edging Past Q2's $388.2M
LNTH has more than doubled off its 52-week low of $50.155.
Summary
Lantheus reported third-quarter revenue of $389.9M, a hair above the $388.2M it booked in Q2, with adjusted EPS of $1.68 and net income of $22.4M. The number lands with the company's $8B takeout by Curium already agreed and shareholder-approved, so the print carries little standalone trading weight — the stock is now a deal story, not an earnings story. Guidance remains suspended pending the merger, and in connection with the pending Curium transaction the company is suspending previously issued full-year 2026 financial guidance, so there is no forward outlook to react to. The real swing factor is regulatory: Lantheus and Curium each received an FTC Second Request on October 22, extending the HSR waiting period, and the earlier HSR refiling already pushed expected timing.
At the time of this announcement, LNTH was trading at $100.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.6B. The 52-week trading range was $50.16 to $111.86. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.